Fundraising FoxTrethera
Sherman Oaks, US · Founded 2013 · Delaware corporation
Find your way into Trethera
Sign up to see every warm intro you have to Trethera
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Trethera team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
Trethera was founded in 2013 by Caius Radu.
CR
Caius RaduFounder
KA
Kenneth A. Schultz, M.D.Executive
JC
Johannes CzerninNamed on SEC filing
Board
LL
Louis L. GondaBoard director
LD
Laurent DuboisBoard director
CM
Carl McKinzieBoard director
TD
Timothy Donahue, M.D.Board director
RB
R. Boyd QuinnellBoard director
JD
Jean deKernionBoard director
Funding
SEC filings, press & company announcements$35.1M disclosed across 8 of 9 rounds · 2015–2025
- Undisclosed amountSeed Funding RoundFeb 2021Source ↗
▶$250KraisedMay 2025 · 1 investors · BiotechnologyRule 506(c)
▶$250KraisedMay 2025 · 1 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Louis L. GondaDirector
- Kenneth A. Schultz, M.D.Executive Officer, Director
- Laurent DuboisDirector
- Carl McKinzieDirector
- Timothy Donahue, M.D.Director
- R. Boyd QuinnellDirector
- Offering amount
- $5M
- Amount sold
- $250K
- Minimum investment
- $50K
- Sales commissions
- $250K
- Placement agents
- Nobles & Richards Inc.
- First sale
- Apr 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$3.8MraisedMay 2022 · 38 investors · BiotechnologyRule 506(b)
▶$3.8MraisedMay 2022 · 38 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jean B. deKernionExecutive Officer, Director
- Louis L. GondaDirector
- Kenneth A. Schultz, M.D.Executive Officer, Director
- Carl W. McKinzieExecutive Officer, Director
- Timothy Donahue, M.D.Director
- Amount sold
- $3.8M
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.3MraisedFeb 2021 · 25 investors · BiotechnologyRule 506(b)
▶$3.3MraisedFeb 2021 · 25 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Carl W. McKinzieExecutive Officer, Director
- Jean B. deKernionExecutive Officer, Director
- Louis L. GondaDirector
- Timothy Donahue, M.D.Director
- Kenneth A. Schultz, M.D.Executive Officer, Director
- Offering amount
- $3.3M
- Amount sold
- $3.3M
- First sale
- Feb 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$580.5KraisedApr 2019 · 5 investors · BiotechnologyRule 506(b)
▶$580.5KraisedApr 2019 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Lynne RollinsExecutive Officer
- Carl W. McKinzieExecutive Officer, Director
- Louis L. GondaDirector
- Jean B. deKernionExecutive Officer, Director
- Kenneth A. Schultz, M.D.Executive Officer, Director
- Timothy Donahue, M.D.Director
- Offering amount
- $10M
- Amount sold
- $580.5K
- First sale
- Apr 2019
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$8.1MraisedMar 2019 · 28 investors · BiotechnologyRule 506(b)
▶$8.1MraisedMar 2019 · 28 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Timothy Donahue, M.D.Director
- Lynne RollinsExecutive Officer
- Carl W. McKinzieExecutive Officer, Director
- Louis L. GondaDirector
- Jean B. deKernionExecutive Officer, Director
- Kenneth A. Schultz, M.D.Executive Officer, Director
- Offering amount
- $8.1M
- Amount sold
- $8.1M
- First sale
- Mar 2019
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$4.2MraisedMar 2017 · 19 investors · BiotechnologyRule 506(b)
▶$4.2MraisedMar 2017 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nathan MataExecutive Officer
- Lynne RollinsExecutive Officer
- Louis L. GondaDirector
- Jean B. deKernionDirector
- Johanna HolldackExecutive Officer, Director
- Carl W. McKinzieExecutive Officer, Director
- Owen Witte, M.D.Director
- Offering amount
- $5M
- Amount sold
- $4.2M
- First sale
- Feb 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$10MraisedOct 2016 · 43 investors · BiotechnologyRule 506(b)
▶$10MraisedOct 2016 · 43 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Johanna HolldackExecutive Officer, Director
- Johannes CzerninDirector
- Lynne RollinsExecutive Officer
- Louis L. GondaDirector
- Caius RaduDirector
- Carl W. McKinzieExecutive Officer, Director
- Jean B. deKernionDirector
- Nathan MataExecutive Officer
- Offering amount
- $20M
- Amount sold
- $10M
- First sale
- Feb 2016
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$4.9MraisedJul 2015 · 26 investors · PharmaceuticalsRule 506(b)
▶$4.9MraisedJul 2015 · 26 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Louis L. GondaDirector
- Johannes CzerninDirector
- Jean deKernionDirector
- Caius RaduDirector
- Carl McKinzieExecutive Officer, Director
- Offering amount
- $6M
- Amount sold
- $4.9M
- First sale
- Apr 2015
- Incorporated
- Corporation, California, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who founded Trethera?
- Trethera was founded by Caius Radu in 2013.
- How much funding has Trethera raised?
- Trethera has disclosed $35.1M raised across 8 of its 9 known rounds.
- Where is Trethera headquartered?
- Trethera is headquartered in Sherman Oaks, US.